Online inquiry

IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5026MR)

This product GTTS-WQ5026MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets GP gene. The antibody can be applied in Ebola virus infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NP_066246.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 911829
UniProt ID Q05320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5026MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3087MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APG-101
GTTS-WQ12160MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ11415MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ12853MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ13350MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ29MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ12112MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ15586MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW